Crit Rev Oncog. 2009;15(1-2):1-41.

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud Ø.

J BUON. 2009 Sep;14 Suppl 1:S131-40.

The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia.

Olsnes AM, Hatfield KJ, Bruserud Ø.

Crit Rev Oncog. 2009;15(1):1-36.

Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud O.

Cytotherapy. 2009;11(6):749-60.

Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators.

Akkök CA, Liseth K, Hervig T, Ryningen A, Bruserud Ø, Ersvaer E.

Curr Cancer Drug Targets. 2009 Sep;9(6):761-76.

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

Reikvam H, Ersvaer E, Bruserud O.

Hematology. 2009 Aug;14(4):224-6. doi: 10.1179/102453309X439782.

Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.

Bruserud Ø, Håvardstein K.

Transfusion. 2009 Aug;49(8):1709-19.

Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells.

Liseth K, Ersvær E, Abrahamsen JF, Nesthus I, Ryningen A, Bruserud Ø.

Br J Haematol. 2009 Jun;145(6):761-74. Epub 2009 Apr 20.

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.

Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø.

Stem Cells Dev. 2009 Jul-Aug;18(6):807-12.

Connexins are active participants of hematopoietic stem cell regulation.

Foss B, Hervig T, Bruserud O.

Expert Opin Investig Drugs. 2009 Apr;18(4):433-55.

Targeted therapy in acute myeloid leukaemia: current status and future directions.

Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø.

BMC Cancer. 2009 Mar 5;9:77.

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.

Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT.

Tidsskr Nor Laegeforen. 2009 Feb 26;129(5):416-9.

[Granulocyte transfusion]. [Article in Norwegian]

Reikvam H, Blom US, Kristoffersen E, Liseth K, Bruserud O, Hervig T.

Br J Haematol. 2009 Jan;144(1):53-68. Epub 2008 Oct 30.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.

Leuk Res. 2009 Jun;33(6):779-87. Epub 2008 Nov 12.

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.

Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O.

Transfusion. 2009 Feb;49(2):354-61. Epub 2008 Oct 28.

Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O.